Generic giant Teva Pharmaceuticals will launch the first generic version of Victoza (liraglutide injection 1.8mg) in the U.S, making it the first generic GLP-1 drug to enter the U.S. market. The patent for Novo Nordisk–developed liraglutide is set to expire until November 18, 2024.
Other popular GLP-1 drugs, such as semaglutide (marketed as Ozempic and Wegovy), still maintain patent protection until 2026. Victoza had annual sales of $1.656 billion as of April 2024. “We are pleased to announce the launch of the first generic GLP-1 product in the U.S. marketplace and we hope that it will help improve access and address some of the current challenges,” said a Teva spokesperson.
Pricing and future plans
In terms of pricing, Teva plans on charging $469.60 for the two pack and $704.40 for the three pack versions of the drug.
“Teva looks forward to bringing our first to file Gx Saxenda to the market at the appropriate time, and will continue to evaluate future opportunities in this space,” a spokesperson said.
In a press release, Ernie Richardsen, SVP and head of U.S. commercial generics at Teva, underscored that this launch not only provides patients with type 2 diabetes another treatment option but also strengthens the company’s generics portfolio.
Liraglutide indications
Liraglutide injection, the active ingredient in Teva’s newly launched generic, has a number of impacts on metabolism. It is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Additionally, it has been shown to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Victoza (liraglutide) is indicated to improve glycemic control in patients 10 years and older with type 2 diabetes, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with the condition and a history of cardiovascular disease. Another version of the drug marketed as Saxenda is indicated for weight loss.
Filed Under: Cardiovascular, Metabolic disease/endicrinology
